Douglas V. Faller

Douglas V. Faller

Auto-generated profile, based on publicly available information

Douglas V. Faller

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1999 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Closed access
PDF file
DFDouglas V Faller
Douglas V Faller

21 November 2006 in Blood
Verified
Journal Article
Open access
PDF file
SPSusan P. Perrine
Susan P. Perrine
OHOlivier Hermine
Olivier Hermine
TSTrudy Small
Trudy Small
FSFelipe Suarez
Felipe Suarez
RORichard O'Reilly
Richard O'Reilly
DFDouglas V. Faller
Douglas V. Faller
Malignancies associated with latent Epstein-Barr virus (EBV) are resistant to nucleoside-type antiviral agents because the viral enzyme target of these antiviral drugs, thymidine kinase (TK), is not expressed. Short-chain fatty acids, such as butyrate, induce EBV-TK expression in latently infected B cells. As butyrate has been shown to sensitize EBV+ lymphoma cells in vitro to apoptosis induced by ganciclovir, arginine butyrate in combination with ganciclovir was administered in 15 patients with refractory EBV+ lymphoid malignancies to evaluate the drug combination for toxicity, pharmacokinetics, and clinical responses. Ganciclovir was administered twice daily at standard doses, and arginine butyrate was administered by continuous infusion in an intrapatient dose escalation, from 500 mg/(kg/day) escalating to 2000 mg/(kg/day), as tolerated, for a 21-day cycle. The MTD for arginine butyrate in combination with ganciclovir was established as 1000 mg/(kg/day). Ten of 15 patients showed significant antitumor responses, with 4 CRs and 6 PRs within one treatment cycle. Complications from rapid tumor lysis occurred in 3 patients. Reversible somnolence or stupor occurred in 3 patients at arginine butyrate doses of greater than 1000 mg/(kg/day). The combination of arginine butyrate and ganciclovir was reasonably well-tolerated and appears to have significant biologic activity in vivo in EBV+ lymphoid malignancies which are refractory to other regimens.

1 August 2012 in BioResearch Open Access
Verified
Journal Article
Open access
KSKosta Steliou
Kosta Steliou
MBMichael S. Boosalis
Michael S. Boosalis
SPSusan P. Perrine
Susan P. Perrine
JSJosé Sangerman
José Sangerman
DFDouglas V. Faller
Douglas V. Faller
In addition to being a part of the metabolic fatty acid fuel cycle, butyrate is also capable of inducing growth arrest in a variety of normal cell types and senescence-like phenotypes in gynecological cancer cells, inhibiting DNA synthesis and cell growth in colonic tumor cell lines, suppressing hTERT mRNA expression and telomerase activity in human prostate cancer cells, and inducing stem cell differentiation and apoptosis by DNA fragmentation. It regulates gene expression by inhibiting histone deacetylases (HDACs), enhances memory recovery and formation in mice, stimulates neurogenesis in the ischemic brain, promotes osteoblast formation, selectively blocks cell replication in transformed cells (compared to healthy cells), and can prevent and treat diet-induced obesity and insulin resistance in mouse models of obesity, as well as stimulate fetal hemoglobin expression in individuals with hematologic diseases such as the thalassemias and sickle-cell disease, in addition to a multitude of other biochemical effects in vivo. However, efforts to exploit the potential of butyrate in the clinical treatment of cancer and other medical disorders are thwarted by its poor pharmacological properties (short half-life and first-pass hepatic clearance) and the multigram doses needed to achieve therapeutic concentrations in vivo. Herein, we review some of the methods used to overcome these difficulties with an emphasis on HDAC inhibition.

29 March 2018 in Blood
Verified
Journal Article
Open access
PDF file
RSRonan T. Swords
Ronan T. Swords
SCSteven Coutre
Steven Coutre
MMMichael B. Maris
Michael B. Maris
JZJoshua F. Zeidner
Joshua F. Zeidner
JFJames M. Foran
James M. Foran
MSMichael R. Savona
Michael R. Savona
Key Points: RP2D of PEV 20 mg/m2 in PEV/AZA combo did not alter toxicity profile of AZA; dose-limiting toxicities were transiently elevated AST/ALT. In treatment-naive older AML patients, the intent-to-treat ORR was 50%.

26 January 2012 in Blood
Verified
Journal Article
Open access
PDF file
SGSajal K. Ghosh
Sajal K. Ghosh
SPSusan P. Perrine
Susan P. Perrine
RWRobert M. Williams
Robert M. Williams
DFDouglas V. Faller
Douglas V. Faller
Induction of EBV lytic-phase gene expression, combined with exposure to an antiherpes viral drug, represents a promising targeted therapeutic approach to EBV-associated lymphomas. Short-chain fatty acids or certain chemotherapeutics have been used to induce EBV lytic-phase gene expression in cultured cells and mouse models, but these studies generally have not translated into clinical application. The recent success of a clinical trial with the pan-histone deacetylase (pan-HDAC) inhibitor arginine butyrate and the antiherpes viral drug ganciclovir in the treatment of EBV lymphomas prompted us to investigate the potential of several HDAC inhibitors, including some new, highly potent compounds, to sensitize EBV+ human lymphoma cells to antiviral agents in vitro. Our study included short-chain fatty acids (sodium butyrate and valproic acid); hydroxamic acids (oxamflatin, Scriptaid, suberoyl anilide hydroxamic acid, panobinostat [LBH589], and belinostat [PXD101]); the benzamide MS275; the cyclic tetrapeptide apicidin; and the recently discovered HDAC inhibitor largazole. With the exception of suberoyl anilide hydroxamic acid and PXD101, all of the other HDAC inhibitors effectively sensitized EBV+ lymphoma cells to ganciclovir. LBH589, MS275, and largazole were effective at nanomolar concentrations and were 104 to 105 times more potent than butyrate. The effectiveness and potency of these HDAC inhibitors make them potentially applicable as sensitizers to antivirals for the treatment of EBV-associated lymphomas.

30 January 2013 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
ATAsami Takashima
Asami Takashima
DFDouglas V Faller
Douglas V Faller
(2013). Targeting the RAS oncogene. Expert Opinion on Therapeutic Targets: Vol. 17, No. 5, pp. 507-531.